MEK-inhibitor (inh) and hydroxychloroquine (HCQ) in <i>KRAS</i>-mutated advanced pancreatic ductal adenocarcinoma (PDAC).
Maahum Mehdi(Medical College of Wisconsin), Mandana Kamgar(Medical College of Wisconsin), Gulrayz Ahmed(Medical College of Wisconsin), Carolyn Oxencis(Froedtert Hospital), Beth Erickson(Medical College of Wisconsin), Susan Tsai(The Ohio State University Wexner Medical Center), Samih Z Thalji(Medical College of Wisconsin), Razelle Kurzrock(Medical College of Wisconsin), Kathleen K. Christians(Medical College of Wisconsin), Thomas McFall(Salk Institute for Biological Studies), Mohammed Aldakkak(Medical College of Wisconsin), Douglas B. Evans(The University of Texas MD Anderson Cancer Center), Omid Yazdanpanah(Wayne State University), Sakti Chakrabarti(Mayo Clinic in Arizona), Aditya Shreenivas(City Of Hope National Medical Center), Bicky Thapa(Cleveland Clinic), Ben George(Medical College of Wisconsin), William A. Hall(Medical College of Wisconsin), James P. Thomas(Medical College of Wisconsin), Mary Beth Holden(Medical College of Wisconsin)
Cited by 7
Related Papers
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
|Molecular Cancer Therapeutics|2017|2.4k
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
|Molecular Cancer Therapeutics|2015|2.3k
Epstein-Barr Virus and Cancer
|Clinical Cancer Research|2004|795
Review of precision cancer medicine: Evolution of the treatment paradigm
|Cancer Treatment Reviews|2020|747
Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study
|Nature Medicine|2019|710